Lantern Pharma to Report Fourth Quarter and Fiscal Year 2022 Operating & Financial Results on March 20, 2023 at 4:30 p.m. ET
March 13 2023 - 8:00AM
Business Wire
- Webcast to be held Monday, Mar. 20, 4:30 p.m. ET, register
here, or at the link below.
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage
biopharmaceutical company using its proprietary RADR® artificial
intelligence (AI) and machine learning (ML) platform to transform
the cost, pace, and timeline of oncology drug discovery and
development, today announced that it will host its fourth quarter
and fiscal year 2022 financial results webcast on Monday, March 20,
2023 at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time.
Management intends to discuss the operating and financial
results for the fourth quarter and fiscal year ended December 31,
2022 and provide guidance on upcoming milestones. Panna Sharma,
President and Chief Executive Officer of Lantern Pharma, will lead
the call and will be joined by other members of the management
team.
To register for the webcast, sign up at the link below:
https://us06web.zoom.us/webinar/register/3616775268267/WN_94qgn_1IRnuRALmciLu0CQ.
A replay of the webcast will be available after the call on the
investor relations section of the Company's website at
ir.lanternpharma.com.
About Lantern Pharma Lantern Pharma (NASDAQ: LTRN) is a
clinical-stage oncology-focused biopharmaceutical company
leveraging its proprietary RADR® AI and machine learning platform
to discover biomarker signatures that identify patients most likely
to respond to its pipeline of genomically-targeted therapeutics. By
targeting drugs to patients whose genomic profile identifies them
as having the highest probability of benefiting from the drug,
Lantern's approach represents the potential to deliver
best-in-class outcomes.
Please find more information at: Website: www.lanternpharma.com
LinkedIn: https://www.linkedin.com/company/lanternpharma/ Twitter:
@lanternpharma Lantern’s Monthly Newsletter – SPARK: Sign-up
here
Forward-looking Statements: This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These forward-looking
statements include, among other things, statements relating to:
future events or our future financial performance; the potential
advantages of our RADR® platform in identifying drug candidates and
patient populations that are likely to respond to a drug candidate;
our strategic plans to advance the development of our drug
candidates and antibody drug conjugate (ADC) development program;
estimates regarding the development timing for our drug candidates
and ADC development program; expectations and estimates regarding
clinical trial timing and patient enrollment; our research and
development efforts of our internal drug discovery programs and the
utilization of our RADR® platform to streamline the drug
development process; our intention to leverage artificial
intelligence, machine learning and genomic data to streamline and
transform the pace, risk and cost of oncology drug discovery and
development and to identify patient populations that would likely
respond to a drug candidate; estimates regarding patient
populations, potential markets and potential market sizes; sales
estimates for our drug candidates and our plans to discover and
develop drug candidates and to maximize their commercial potential
by advancing such drug candidates ourselves or in collaboration
with others. Any statements that are not statements of historical
fact (including, without limitation, statements that use words such
as "anticipate," "believe," "contemplate," "could," "estimate,"
"expect," "intend," "seek," "may," "might," "plan," "potential,"
"predict," "project," "target," "model," "objective," "aim,"
"upcoming," "should," "will," "would," or the negative of these
words or other similar expressions) should be considered
forward-looking statements. There are a number of important factors
that could cause our actual results to differ materially from those
indicated by the forward-looking statements, such as (i) the impact
of the COVID-19 pandemic, (ii) the risk that our research and the
research of our collaborators may not be successful, (iii) the risk
that none of our product candidates has received FDA marketing
approval, and we may not be able to successfully initiate, conduct,
or conclude clinical testing for or obtain marketing approval for
our product candidates, (iv) the risk that no drug product based on
our proprietary RADR® AI platform has received FDA marketing
approval or otherwise been incorporated into a commercial product,
and (v) those other factors set forth in the Risk Factors section
in our Annual Report on Form 10-K for the year ended December 31,
2021, filed with the Securities and Exchange Commission on March
10, 2022. You may access our Annual Report on Form 10-K for the
year ended December 31, 2021 under the investor SEC filings tab of
our website at www.lanternpharma.com or on the SEC's website at
www.sec.gov. Given these risks and uncertainties, we can give no
assurances that our forward-looking statements will prove to be
accurate, or that any other results or events projected or
contemplated by our forward-looking statements will in fact occur,
and we caution investors not to place undue reliance on these
statements. All forward-looking statements in this press release
represent our judgment as of the date hereof, and, except as
otherwise required by law, we disclaim any obligation to update any
forward-looking statements to conform the statement to actual
results or changes in our expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230313005150/en/
Nicole Leber Investor Relations Associate
ir@lanternpharma.com
Lantern Pharma (NASDAQ:LTRN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lantern Pharma (NASDAQ:LTRN)
Historical Stock Chart
From Jul 2023 to Jul 2024